DES/HXC/jam February 8, 2011 PATENT APPLICATION DOCKET NO.: 3518.1015-000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thomas M. DiMauro, Mohamed Attawia, Hassan Serhan, Martin A.

Reynolds, Melissa Grace, Sudhakar Kadiyala, David Urbahns, Scott Bruder, Gregory Collins, Laura J. Brown, Jeff Geesin, Pamela L. Plouhar, Catherine

Smith and John Siekierka

Application No.: 10/630,227 Group: 1647

Filed: July 30, 2003 Examiner: Shafer, Shulamith H.

Confirmation No.: 8291

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

For: Trans-Capsular Administration Of High Specificity Cytokine Inhibitors Into

Orthopedic Joints

CERTIFICATE OF	MAILING OR TRANSMISSION		
I hereby certify that this con	respondence is being deposited with the United		
	icient postage as First Class Mail in an		
	ssioner for Patents, P.O. Box 1450, Alexandria		
VA 22313-1450, or is being facsimile transmitted to the United States Patent			
and Trademark Office on:			
and Trademark Office on:			
and Trademark Office on: Date	Signature		
Date			

TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:		
This Ir	nformation Disclosure Statement is submitted:	
\boxtimes	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits; or before the mailing of a i office action after the filing of a Request for Continued Examination).	
	under 37 CFR 1.97(c) together with either: a Statement under 37 CFR 1.97(e), as checked below, or a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before any of a final action, notice of allowance, or an action that closes prosecution, whichever occus first)	
	under 37 CFR 1.97(d) together with: a Statement under 37 CFR 1.97(e), as checked below, and a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action, notice of allowance, whichever occurs first, or if prosecution otherwise closes, but on or before payment of the issue fee)	
	under 37 CFR 1.97(i):	

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e) П Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or П No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Statement Under 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000 П Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. \boxtimes Enclosed herewith is a Listing of References. Copies of the cited references are enclosed except as indicated below or in the attached Listing of References. Copies of the cited references submitted with an Information Disclosure Statement in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed, are not required under 37 CFR 1.98(d)(1) and (2) and are thus not provided. П The listed references were cited in the enclosed Search Report in counterpart foreign application [add application number], which is listed in the attached Listing of References. \boxtimes The "concise explanation" requirement (non-English references) for references, C162 and C164 under 37 CFR 1.98(a)(3) is satisfied by: the explanation provided on the attached sheet. the explanation provided in the Specification. submission of the enclosed International Search Report. submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

-2-

 \boxtimes

the enclosed English language abstract.

Metho	od of payment:		
	Authorization is NOT granted to charge any fees which may be due in this matter to our Deposit Account.		
	Please charge Deposit Account 08-0380 in the amount of \$[].		
	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.		
\boxtimes	Please charge any deficiency in fees and credit any overpayment to Deposit Accounts 08-0380.		
	R	espectfully submitted,	
	H	IAMILTON, BROOK, SMITH & REYNOLDS, P.C.	
	В	By /Hak J. Chang, Reg. No. 56,319/	
		lak J. Chang	
		Legistration No. 56,319	
		elephone: (978) 341-0036	
_		acsimile: (978) 341-0136	
	ord, MA 01742-9133		
Dated: February 08, 2011			

-3-